Form 4: Inhibrx Biosciences Director Douglas Forsyth Granted 15,000 Stock Options

Inhibrx Biosciences, Inc. director Douglas Forsyth was granted 15,000 stock options with an exercise price of $12.91, aligning his interests with shareholder value.

Summary

• Douglas Forsyth, a Director of Inhibrx Biosciences, Inc. (INBX), was granted 15,000 stock options.
• The transaction date for this acquisition was May 28, 2025.
• Each stock option has an exercise price of $12.91.
• The options will become fully exercisable on May 28, 2026, contingent upon Mr. Forsyth's continued service.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Mr. Forsyth directly beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it represents a standard, value-aligning compensation event for a director, indicating continued commitment and incentivization. It is not a major market-moving event but reflects normal corporate governance.

Positives

• The grant of stock options to a director aligns management's and the board's interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• This type of compensation is a standard practice to incentivize long-term commitment and performance from key personnel.

Negatives

• No direct negative implications are present in this routine insider transaction filing.

Risks

• The value of the stock options is dependent on the future market price of Inhibrx Biosciences' common stock; if the stock price does not exceed the exercise price of $12.91, the options may expire worthless.
• The options are subject to a vesting schedule, requiring Douglas Forsyth's continued service through May 28, 2026, for them to become fully exercisable.

Future Outlook

The stock option grant serves as a forward-looking incentive for the director, tying a portion of his compensation to the future performance and growth of Inhibrx Biosciences' stock price over the next decade.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and broader public company sectors. It is a standard component of executive and board compensation packages designed to attract, retain, and motivate talent by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly within the biotechnology sector, where long-term incentives are crucial.
• The vesting period and expiration date are typical for such grants, comparable to similar compensation structures observed at companies like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD) for their non-employee directors, though specific grant sizes and exercise prices vary based on company size, performance, and individual roles.

Corporate Governance

Related Party Transactions

• The grant of 15,000 stock options to Douglas Forsyth, a director of Inhibrx Biosciences, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options' profitability depends on the company's stock price appreciation.
• Employees: While not directly impacting employees, such compensation practices for leadership can signal stability and a commitment to long-term growth, which indirectly benefits the broader employee base.

Next Steps

• The stock options will become fully exercisable on May 28, 2026, provided Douglas Forsyth continues his service as a director.

Key Dates

Keywords

Inhibrx Biosciences, INBX, Form 4, stock option, insider transaction, director compensation, equity grant, beneficial ownership